HSBC Call 42 BAYN 13.12.2028/ DE000HS57EV0 /
15/11/2024 8:40:20 | Diferencia+0.050 | Bid13:05:15 | Ask13:05:15 | Subyacente | Precio de ejercicio | Fecha de expiración | Tipo de opción |
---|---|---|---|---|---|---|---|
0.240EUR | +26.32% | 0.250 Volumen de oferta: 50,000 |
0.280 Tamaño/ Volumen/ Formato de Ask: 50,000 |
BAYER AG NA O.N. | 42.00 EUR | 13/12/2028 | Call |
GlobeNewswire
02/08
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire
11/07
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire
30/05
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
30/05
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
28/05
Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
GlobeNewswire
02/05
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
18/04
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
16/04
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
11/04
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
25/03
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
06/03
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
04/03
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
15/02
2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página